Navigation Links
Immunodeficiency in Medical Technology

GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting

... vaccines for diseases caused by the HIV-1 (Human immunodeficiency Virus), and other infectious agents, today ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced the ... people. Therapeutic trials of a simian immunodeficiency virus (SIV) prototype of the GeoVax HIV vaccine ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ...

GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced ... HIV-1 virus infection which causes Acquired immunodeficiency Disease (AIDS). The Seattle meeting also ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ...

GeoVax Reports Progress on Its AIDS Vaccine Technology

... pilot study on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously

... dose via a single site to patients with primary immunodeficiency (PID). The results were presented at the annual ... the architecture of the tissue. About Primary immunodeficiency Disorders Primary immunodeficiency disorders encompass more than 100 diseases caused ...

Adult Circumcision Reduces Risk of HIV Transmission Without Reducing Sexual Pleasure

... show that adult circumcision reduces the risk of contracting the human immunodeficiency virus (HIV) and the risk of coital injury -- without reducing pleasure or ... Remnant foreskin contains fewer Langerhans' cells--implications for human immunodeficiency transmission in circumcised men. J Urol, suppl. 2009: 181, 4, abstract ....

IBT Laboratories Expands its Menu of Tests for Immune Deficiency

... of patients whose immune systems may be compromised due to a primary immunodeficiency disorder, chemotherapy drugs, or because they are taking ... mononuclear cells from whole blood, will help physicians identify primary immunodeficiency in children with recurrent infections. For transplant populations, ...

Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds

... and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced ... for Human Use (CHMP) to extend the drug's indication to treat human immunodeficiency virus (HIV-1) infection to include treatment-experienced adult ....

GeoVax Secures $10 Million Financing Commitment

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's HIV/AIDS vaccine technology ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results

... HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS) caused by the virus known as HIV-1 by vaccinating ... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ...

GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is covered ... GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating ...

GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update

... HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS) caused by the virus known as HIV-1 by vaccinating ... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ...

Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ... GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating ...

GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ... GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating ...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

... of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act as alternative substrates for the ...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

... placebo-controlled Phase 3 study monitored 405 patients with idiopathic PAH or PAH associated with anorexigen use, connective tissue disease, human immunodeficiency virus (HIV) infection, or congenital systemic-to-pulmonary shunts. Patients were randomized in groups and received one of five treatments, ...

Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences

... of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for ...

IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant

... rate can be as high as 90%. About Valcyte Valcyte tablets are indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Valcyte is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. ...

Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009

... particles from the human circulatory system. The device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats. The Hemopurifier(R) also holds ...

Novel Vaccine Approach Offers Hope in Fight Against HIV

... that produces molecules that block infection, the scientists protected monkeys from infection by a virus closely related to HIV -- the simian immunodeficiency virus, or SIV -- that causes AIDS in rhesus monkeys. "We used a leapfrog strategy, bypassing the natural immune system response that was the ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. R7128, an oral treatment for chronic HCV infection, has completed a ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. R7128, an oral treatment for chronic HCV infection, has completed a 4-week ...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

... treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. R7128, an oral treatment for chronic HCV infection, has completed a 4-week ...

Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling ...

Pharmasset Reports Fiscal Year End 2008 Financial Results

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is ...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations

... for two vaccines in over 40 million doses with no significant side effects. The Company's disease focus presently includes malaria and the human immunodeficiency virus. For further information regarding the Company and its mucosal approach, please visit http://www.mymetics.com . Safe Harbor ...

Pharmasset Reports Financial Results for Quarter Ended June 30, 2008

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference

... monotherapy study of RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV), demonstrating robust antiviral activity with a well-tolerated profile. An oral presentation of the data was given today by Dr. Graeme ...

Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines

... commitment to fighting HIV/AIDS, please visit http://www.abbott.com/hiv . About Kaletra Indication KALETRA (lopinavir/ritonavir) is a human immunodeficiency virus-1 (HIV-1) protease inhibitor. KALETRA is always used in combination with other anti-HIV-1 medicines for the treatment of HIV-1 infection. ...

Protein Key to Control Growth of Blood Cells

... for cancer patients after high dose chemotherapy or radiotherapy and treatments for particular blood disorders. Aplastic anemia, severe combined immunodeficiency and hemoglobin disorders, for example, involve deficiencies of specific immune cells in the blood. Using a drug to inhibit Lnk could potentially ...

Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is in Phase 3 ...

Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells

... to evade infection and destruction leaving them able fight opportunistic infections and HIV itself. About HIV/AIDS and CCR5 HIV stands for Human immunodeficiency Virus. HIV infection kills or impairs cells of the immune system, progressively destroying the body's ability to fight infections and certain cancers ...

Pharmasset Receives Notice of Allowance

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing

... monotherapy study of RDEA806, its novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with human immunodeficiency virus (HIV). These additional results demonstrated that once-daily dosing with the enteric-coated tablet formulation of RDEA806 resulted in ...

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations

... with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology, virology -- including human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections -- and oncology. Progenics, in collaboration with Wyeth, is developing RELISTOR(TM) ...
Other Contents
(Date:8/27/2014)... Warwick research finds , Gamblers show the same ... research has shown. , Researchers, led by Dr Elliot ... conducted tests that found that both human gamblers and ... than low-value rewards. , Published in Biology Letters ... the important role that memories of previous biggest wins ...
(Date:8/26/2014)... colony of harmful bacteria, biofilms make the treatment ... a biofilm pose a significant health risk due ... and biofilm-protected bacteria account for some 80 percent ... 50 to 1,000 times more resistant to antibiotics ... may have stumbled onto a magic bullet," said ...
(Date:8/26/2014)... years, increasing pressure from policymakers, consumers, and suppliers ... go beyond reducing the pollutants they emit from ... Today companies must also assess environmental performance at ... of primary materials to the use and recycling ... rise to the discipline known as life cycle ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2
(Date:8/27/2014)... 27, 2014 The extensive polling ... by healthcare research group Black Book Rankings uncovers ... adequately staffed, supplied or built to care for ... initiated this annual survey to gain stakeholder insight ... control, epidemiology and emergency preparedness systems,” said Doug ...
(Date:8/27/2014)... WEDNESDAY, Aug. 27, 2014 (HealthDay News) -- Pouring half a glass ... much, according to a new study. Researchers asked 74 college ... settings and from bottles that had varying amounts of wine in ... normal. Those who had a "rule of thumb" about how ... glass or two fingers from the top -- poured less wine ...
(Date:8/27/2014)... 27, 2014 Connor Sports has ... World Cup in Spain at the Barcelona, Bilbao, Gran ... FIBA Equipment & Venue Centre Partner since 1994 and Official ... six courts will bear the Connor Sports logo and tagline ... globe on the ESPN broadcasts of the FIBA World Cup. ...
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Picture, if ... not Holmes and Watson but more of a Mr. Inside, ... Davis, in terms of personalities and world view. This Mr. ... University of Texas at Austin, and Mr. Outside was an ... family physician, his new girlfriend, and a gaggle of teenagers ...
(Date:8/27/2014)... NC. SonaCare Medical, LLC, the global ... sales of 15 HIFU devices over the past twelve ... for the company’s ablation technology. , “It is ... achieved over the past year, especially since we are ... our most active sales period,” says Mike Klein, CEO ...
Breaking Medicine News(10 mins):Health News:American Hospitals Are Vastly Unprepared for Ebola Patients, Reveals Black Book™ Survey of Emergency Physicians, Nurses and Infection Control Practitioners 2Health News:American Hospitals Are Vastly Unprepared for Ebola Patients, Reveals Black Book™ Survey of Emergency Physicians, Nurses and Infection Control Practitioners 3Health News:American Hospitals Are Vastly Unprepared for Ebola Patients, Reveals Black Book™ Survey of Emergency Physicians, Nurses and Infection Control Practitioners 4Health News:'Half a Glass' Rule May Curb Overdrinking 2Health News:Connor Sports® Provides Six Custom Courts for 2014 FIBA World Cup - Time-Lapse Video of FIBA Courts Production Released 2Health News:Connor Sports® Provides Six Custom Courts for 2014 FIBA World Cup - Time-Lapse Video of FIBA Courts Production Released 3Health News:UW Rankin Self-Publishes Debut Novel, Sublimity: Perchance to Dream, A Speculative Science Mystery 2Health News:SonaCare Medical Announces Twelve Months Sales Results of Fifteen HIFU Devices 2
Other TagsOther Tags